300181.SZ
佐力药业
SZSE · Healthcare · C 制造业 · CN
CNY 13.98
−1.20%Year over year
Reported trailing growth
- Revenue
- +14.1%
- EBITDA
- —
- EBIT
- +21.7%
- EPS
- +19.3%
- Free cash flow
- +412.5%
- Operating cash flow
- +181.1%
Forward estimates
Based on analyst estimates
- Revenue
- -70.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +19.0%
- EBITDA
- +28.7%
- EBIT
- +31.5%
- Net income
- +32.3%
- EPS
- +26.9%
- Free cash flow
- -3.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026